Concentra finds latest acquisition attempt harder to swallow as Atea rejects 'undervalued' offer

After swooping in to pluck Jounce Therapeutics out of the clutches of another potential buyer, Concentra Biosciences could have been forgiven for thinking its next acquisition just weeks later would be another slam dunk. But the latest target, Atea Pharmaceuticals, is proving to be less obliging.